Guidelines Updated for Nonoccupational Postexposure Prophylaxis for HIV
By Elana Gotkine HealthDay Reporter
FRIDAY, May 9, 2025 -- Updated recommendations for antiretroviral nonoccupational postexposure prophylaxis (nPEP) for HIV have been published in the May 8 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Mary R. Tanner, M.D., from the CDC in Atlanta, and colleagues updated the 2016 nPEP guidelines and considerations for use in the United States, including considerations for testing and nPEP regimens for persons exposed who have received long-acting injectable antiretroviral agents in the past.
The authors note that for most adults and adolescents, the preferred regimens are bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir plus (tenofovir alafenamide or tenofovir disoproxil fumarate) plus (emtricitabine or lamivudine). The regimens can be tailored to specific clinical circumstances. For persons prescribed nPEP, medical follow-up should also be tailored to the clinical situation; recommended follow-up includes a remote or in-person visit with a medical provider at 24 hours and clinical follow-up at four to six and 12 weeks after exposure for laboratory testing. Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case of repeat or continuing exposure after the nPEP course. PrEP options should be offered to those with ongoing indications, and an nPEP-to-PrEP transition plan should be created.
"Communication and education strategies are needed to increase both provider and community awareness of nPEP," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Racialized Economic Segregation Linked to Advanced Cancer Diagnosis
FRIDAY, Aug. 1, 2025 -- People living in racially and economically segregated neighborhoods are more likely to be diagnosed with advanced-stage breast and cervical cancer...
New Subtype of Diabetes Identified in Sub-Saharan Africans, Black Americans
FRIDAY, Aug. 1, 2025 -- A new diabetes subtype has been identified in Sub-Saharan Africans and Black Americans, according to a study published online July 21 in The Lancet...
Changes in Missouri Law Linked to Increased Breast Cancer Screening Rates
THURSDAY, July 31, 2025 -- Changes in Missouri law expanding breast cancer screening coverage have led to increased screening rates among Medicaid patients and an increased...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.